These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 16896290)

  • 1. Advances in the treatment of juvenile dermatomyositis.
    Stringer E; Feldman BM
    Curr Opin Rheumatol; 2006 Sep; 18(5):503-6. PubMed ID: 16896290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Juvenile dermatomyositis in the Nice area: a retrospective study 1991-2001].
    Jäger C; Sirvent N; Rabasse N; Soler C; Sebag F; Boutte P; Lacour JP
    Ann Dermatol Venereol; 2002 Oct; 129(10 Pt 1):1120-4. PubMed ID: 12442123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Juvenile dermatomyositis: diagnosis and treatment].
    Gissinger-Prévot S; Figarella-Branger D; Mancini J; Chabrol B
    Arch Pediatr; 2008 Jan; 15(1):50-3. PubMed ID: 18164188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients.
    Cooper MA; Willingham DL; Brown DE; French AR; Shih FF; White AJ
    Arthritis Rheum; 2007 Sep; 56(9):3107-11. PubMed ID: 17763414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ten-year experience of juvenile dermatomyositis: a retrospective study.
    Chiu SK; Yang YH; Wang LC; Chiang BL
    J Microbiol Immunol Infect; 2007 Feb; 40(1):68-73. PubMed ID: 17332910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis. A review of efficacy and safety.
    Riley P; Maillard SM; Wedderburn LR; Woo P; Murray KJ; Pilkington CA
    Rheumatology (Oxford); 2004 Apr; 43(4):491-6. PubMed ID: 14722349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. National registry of patients with juvenile idiopathic inflammatory myopathies in Hungary--clinical characteristics and disease course of 44 patients with juvenile dermatomyositis.
    Constantin T; Ponyi A; Orbán I; Molnár K; Dérfalvi B; Dicso F; Kálovics T; Müller J; Garami M; Sallai A; Balogh Z; Szalai Z; Fekete G; Dankó K
    Autoimmunity; 2006 May; 39(3):223-32. PubMed ID: 16769656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Juvenile dermatomyositis: extramuscular manifestations and their management.
    Lowry CA; Pilkington CA
    Curr Opin Rheumatol; 2009 Nov; 21(6):575-80. PubMed ID: 19730375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety.
    Al-Mayouf SM; Laxer RM; Schneider R; Silverman ED; Feldman BM
    J Rheumatol; 2000 Oct; 27(10):2498-503. PubMed ID: 11036850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Two children with skin rash and muscle weakness: juvenile dermatomyositis].
    Boogaard R; Drexhage VR; van Suijlekom-Smit LW
    Ned Tijdschr Geneeskd; 2005 Jan; 149(3):146-50. PubMed ID: 15693592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Intravenously-administered immunoglobulins as first-choice agent in juvenile dermatomyositis].
    Breems DA; de Haas PW; Visscher F; Sabbe LJ; Busch HF; van Doorn PA
    Ned Tijdschr Geneeskd; 1993 Sep; 137(39):1979-82. PubMed ID: 8413708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab for the treatment of the skin manifestations of dermatomyositis: a report of 3 cases.
    Dinh HV; McCormack C; Hall S; Prince HM
    J Am Acad Dermatol; 2007 Jan; 56(1):148-53. PubMed ID: 17097377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting the course of juvenile dermatomyositis: significance of early clinical and laboratory features.
    Stringer E; Singh-Grewal D; Feldman BM
    Arthritis Rheum; 2008 Nov; 58(11):3585-92. PubMed ID: 18975314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Dermatomyositis in children: clinical course of 9 cases].
    García Consuegra J; Antelo MC; Torreblanca J
    An Esp Pediatr; 1987 Nov; 27(5):362-6. PubMed ID: 3439658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictability of the clinical course of juvenile dermatomyositis based on initial muscle biopsy: a retrospective study of 72 patients.
    Miles L; Bove KE; Lovell D; Wargula JC; Bukulmez H; Shao M; Salisbury S; Bean JA
    Arthritis Rheum; 2007 Oct; 57(7):1183-91. PubMed ID: 17907236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis.
    Riley P; McCann LJ; Maillard SM; Woo P; Murray KJ; Pilkington CA
    Rheumatology (Oxford); 2008 Jun; 47(6):877-80. PubMed ID: 18403404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical assessment in juvenile dermatomyositis.
    Ravelli A; Ruperto N; Trail L; Felici E; Sala E; Martini A
    Autoimmunity; 2006 May; 39(3):197-203. PubMed ID: 16769653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical case of the month. 3-year-old boy presenting with a hand rash. Juvenile dermatomyositis.
    Kendrick CG; Poole JC; Nicotri T; Gedalia A; Lopez FA
    J La State Med Soc; 2004; 156(5):235-9; quiz 240. PubMed ID: 15554092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of intravenous immunoglobulin in the treatment of juvenile dermatomyositis: adverse reactions are associated with immunoglobulin A content.
    Manlhiot C; Tyrrell PN; Liang L; Atkinson AR; Lau W; Feldman BM
    Pediatrics; 2008 Mar; 121(3):e626-30. PubMed ID: 18299304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical features of patients with juvenile and adult dermatomyositis].
    Szalmás O; Nagy-Vince M; Dankó K; Farkas F
    Orv Hetil; 2015 Sep; 156(37):1491-6. PubMed ID: 26552025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.